Skip to main content

Safety

20
Pipeline Programs
22
Companies
25
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
17
1
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
SildenafilPhase 4
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
SildenafilPhase 4
Medigene
MedigeneGermany - Planegg-Martinsried
1 program
1
MDG1011Phase 1/21 trial
Active Trials
NCT03503968Terminated9Est. Jul 2022
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
6 programs
6
AZD3043Phase 11 trial
AZD7503Phase 11 trial
AZD7594Phase 11 trial
AZD9567 MonohydratPhase 11 trial
AZD9977, oral suspensionPhase 11 trial
+1 more programs
Active Trials
NCT01086813Withdrawn0Est. Apr 2010
NCT05143905Completed56Est. Nov 2022
NCT01636024Completed73Est. Jun 2013
+3 more trials
MicuRx Pharmaceuticals
MicuRx PharmaceuticalsCA - Foster City
3 programs
3
MRX-8Phase 11 trial
Oral single doses of MRX-4Phase 11 trial
Single intravenous doses of MRX-4Phase 11 trial
Active Trials
NCT04649541Completed69Est. Dec 2021
NCT03033342Completed122Est. Feb 2017
NCT03033329Completed90Est. Mar 2018
Idorsia
IdorsiaSwitzerland - Allschwil
1 program
1
ACT-462206 5 mgPhase 11 trial
Active Trials
NCT01954589Completed56Est. Jan 2012
Astellas
AstellasChina - Shenyang
1 program
1
ASP7962Phase 11 trial
Active Trials
NCT01981928Completed48Est. May 2014
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
1 program
1
MOR107Phase 11 trial
Active Trials
NCT03067363Terminated24Est. Mar 2017
Biocorp
BiocorpFrance - Issoire
1 program
1
PRV-3279 or placeboPhase 11 trial
Active Trials
NCT03955666Completed16Est. Dec 2019
Sonoma Pharmaceuticals
1 program
1
SBT115301Phase 11 trial
Active Trials
NCT05388981Completed40Est. Jan 2024
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
SBT115301Phase 1
Sonoma Biotherapeutics
1 program
1
SBT115301Phase 1
NeuroDawn Pharmaceutical
1 program
1
Y-3 for injectionPhase 11 trial
Active Trials
NCT06770491Completed20Est. Sep 2025
Galderma
GaldermaTX - Dallas
1 program
GP0045N/A1 trial
Active Trials
NCT03133325Completed12Est. Jul 2017
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
RD06-04 Cells injectionN/A1 trial
Active Trials
NCT06310811Suspended12Est. Mar 2027
Otsuka
OtsukaJapan - Tokushima
1 program
TolvaptanN/A1 trial
Active Trials
NCT03406286Completed2,067Est. Dec 2024
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
DS-1971PHASE_12 trials
Active Trials
NCT02190058Completed32Est. Nov 2014
NCT02107885Completed64Est. Jul 2014
Yirui Pharma
Yirui PharmaChina - Hangzhou
1 program
Kv1.3 potassium channel blockerPHASE_11 trial
Active Trials
NCT07285967Not Yet Recruiting64Est. Dec 2026
Cinclus Pharma
Cinclus PharmaSweden - Stockholm
1 program
Linaprazan gluratePHASE_11 trial
Active Trials
NCT05627518Completed67Est. Jan 2023
Fosun Pharma
Fosun PharmaAustralia - Sydney
1 program
FCN-338 + AzacitidinePHASE_21 trial
Active Trials
NCT06858618Active Not Recruiting47Est. Dec 2026
Takeda
TakedaTOKYO, Japan
1 program
Azilsartan medoxomil and chlorthalidonePHASE_31 trial
Active Trials
NCT01309828Completed153Est. Oct 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
TakedaAzilsartan medoxomil and chlorthalidone
Fosun PharmaFCN-338 + Azacitidine
MedigeneMDG1011
Yirui PharmaKv1.3 potassium channel blocker
NeuroDawn PharmaceuticalY-3 for injection
Cinclus PharmaLinaprazan glurate
Sonoma PharmaceuticalsSBT115301
AstraZenecaAZD7503
MicuRx PharmaceuticalsMRX-8
BiocorpPRV-3279 or placebo
Quotient TherapeuticsMOR107
MicuRx PharmaceuticalsSingle intravenous doses of MRX-4
MicuRx PharmaceuticalsOral single doses of MRX-4
AstraZenecaAZD9567 Monohydrat
AstraZenecaAZD9977, oral suspension

Showing 15 of 25 trials with date data

Clinical Trials (25)

Total enrollment: 3,467 patients across 25 trials

NCT01309828TakedaAzilsartan medoxomil and chlorthalidone

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Start: Mar 2011Est. completion: Oct 2012153 patients
Phase 3Completed
NCT06858618Fosun PharmaFCN-338 + Azacitidine

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

Start: Aug 2023Est. completion: Dec 202647 patients
Phase 2Active Not Recruiting

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Start: Mar 2018Est. completion: Jul 20229 patients
Phase 1/2Terminated
NCT07285967Yirui PharmaKv1.3 potassium channel blocker

A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

Start: Apr 2026Est. completion: Dec 202664 patients
Phase 1Not Yet Recruiting

A Phase 1 Study of Y-3 in US Healthy Volunteers.

Start: Feb 2025Est. completion: Sep 202520 patients
Phase 1Completed
NCT05627518Cinclus PharmaLinaprazan glurate

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

Start: Nov 2022Est. completion: Jan 202367 patients
Phase 1Completed

Study of Single Doses of SBT115301 in Healthy Participants

Start: Jul 2022Est. completion: Jan 202440 patients
Phase 1Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Start: Dec 2021Est. completion: Nov 202256 patients
Phase 1Completed

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

Start: Nov 2020Est. completion: Dec 202169 patients
Phase 1Completed
NCT03955666BiocorpPRV-3279 or placebo

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

Start: Aug 2019Est. completion: Dec 201916 patients
Phase 1Completed

First in Human Single Ascending Dose Study of MOR107

Start: Feb 2017Est. completion: Mar 201724 patients
Phase 1Terminated
NCT03033329MicuRx PharmaceuticalsSingle intravenous doses of MRX-4

Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Start: Oct 2016Est. completion: Mar 201890 patients
Phase 1Completed
NCT03033342MicuRx PharmaceuticalsOral single doses of MRX-4

Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4

Start: Aug 2016Est. completion: Feb 2017122 patients
Phase 1Completed
NCT02512575AstraZenecaAZD9567 Monohydrat

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Start: Nov 2015Est. completion: Sep 201672 patients
Phase 1Completed
NCT02484729AstraZenecaAZD9977, oral suspension

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Start: Jul 2015Est. completion: Nov 2015196 patients
Phase 1Completed

Multiple Dose Study of DS-1971a

Start: Jul 2014Est. completion: Nov 201432 patients
Phase 1Completed

Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.

Start: Mar 2014Est. completion: Jul 201464 patients
Phase 1Completed

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Start: Nov 2013Est. completion: May 201448 patients
Phase 1Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Start: Sep 2012Est. completion: Jun 201373 patients
Phase 1Completed
NCT01568281AstraZenecaAnastrozole ODF

Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects

Start: Apr 2012Est. completion: Jun 201258 patients
Phase 1Completed
NCT01954589IdorsiaACT-462206 5 mg

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Start: Nov 2011Est. completion: Jan 201256 patients
Phase 1Completed

Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

Start: Mar 2010Est. completion: Apr 20100
Phase 1Withdrawn
NCT06310811UNION therapeuticsRD06-04 Cells injection

Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Start: Mar 2024Est. completion: Mar 202712 patients
N/ASuspended

A Study to Evaluate the Safety Following Injection of GP0045 Compared to Restylane Lyft Lidocaine

Start: Apr 2017Est. completion: Jul 201712 patients
N/ACompleted

Samsca PMS in ADPKD Patients

Start: Jul 2016Est. completion: Dec 20242,067 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

22 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.